CN103966352B - Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 - Google Patents
Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 Download PDFInfo
- Publication number
- CN103966352B CN103966352B CN201410235190.5A CN201410235190A CN103966352B CN 103966352 B CN103966352 B CN 103966352B CN 201410235190 A CN201410235190 A CN 201410235190A CN 103966352 B CN103966352 B CN 103966352B
- Authority
- CN
- China
- Prior art keywords
- seq
- mrna
- pca3
- cst1
- cst4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100038387 Cystatin-SN Human genes 0.000 title claims abstract description 78
- 101000884768 Homo sapiens Cystatin-SN Proteins 0.000 title claims abstract description 77
- 102100028036 Cystatin-S Human genes 0.000 title claims abstract description 73
- 101000722966 Homo sapiens Cystatin-S Proteins 0.000 title claims abstract description 72
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 64
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims abstract description 64
- 238000012360 testing method Methods 0.000 title claims abstract description 24
- 108091033411 PCA3 Proteins 0.000 title claims abstract 16
- 239000000439 tumor marker Substances 0.000 title abstract description 7
- 238000001514 detection method Methods 0.000 claims abstract description 52
- 238000003745 diagnosis Methods 0.000 claims abstract description 18
- 238000012546 transfer Methods 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 10
- 238000011156 evaluation Methods 0.000 claims abstract description 8
- 238000012544 monitoring process Methods 0.000 claims abstract description 7
- 239000000523 sample Substances 0.000 claims description 72
- 108020004999 messenger RNA Proteins 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 28
- 125000003729 nucleotide group Chemical group 0.000 claims description 28
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 230000005291 magnetic effect Effects 0.000 claims description 16
- 239000011324 bead Substances 0.000 claims description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 239000000872 buffer Substances 0.000 claims description 4
- 239000002532 enzyme inhibitor Substances 0.000 claims description 4
- 108091092562 ribozyme Proteins 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000002700 urine Anatomy 0.000 abstract description 24
- 210000002966 serum Anatomy 0.000 abstract description 5
- 238000005070 sampling Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 44
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 39
- 238000000034 method Methods 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 238000011282 treatment Methods 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 11
- 239000013256 coordination polymer Substances 0.000 description 11
- 230000003321 amplification Effects 0.000 description 10
- 230000008859 change Effects 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000003199 nucleic acid amplification method Methods 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 101100008568 Homo sapiens CST4 gene Proteins 0.000 description 9
- 238000011144 upstream manufacturing Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 101100062319 Homo sapiens CST1 gene Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 238000000137 annealing Methods 0.000 description 4
- 210000001124 body fluid Anatomy 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 235000019628 coolness Nutrition 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 210000000582 semen Anatomy 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002485 urinary effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 102000015833 Cystatin Human genes 0.000 description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 108010026774 Salivary Cystatins Proteins 0.000 description 2
- 102000018968 Salivary Cystatins Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000035896 Twin-reversed arterial perfusion sequence Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 108050004038 cystatin Proteins 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 2
- 239000006148 magnetic separator Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001559 fluids and secretion Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- -1 hydroxy propyl Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 101150047761 sdhA gene Proteins 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 108010057210 telomerase RNA Proteins 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
标准品编号 | 浓度(copy/μL) |
STD1 | 100000 |
STD2 | 10000 |
STD3 | 1000 |
STD4 | 100 |
患者编号 | 治疗前后浓度变化百分比 | 临床评价 |
1 | 降低87% | 疗效显著 |
2 | 升高7% | 无效 |
3 | 降低44% | 改善 |
4 | 降低58% | 改善 |
5 | 升高20% | 无效 |
6 | 降低17% | 无效 |
7 | 降低49% | 改善 |
8 | 降低75% | 疗效显著 |
9 | 降低40% | 无效 |
10 | 降低61% | 改善 |
患者编号 | 6周 | 3个月 | 6个月 | 9个月 | 临床评价 |
1 | 0.37 | 0.41 | 0.60 | 0.74 | 转移复发 |
2 | 0.21 | 0.28 | 0.25 | 0.27 | 无进展生存 |
3 | 0.39 | 0.41 | 0.45 | 0.53 | 无进展生存 |
4 | 0.25 | 0.30 | 0.26 | 0.31 | 无进展生存 |
5 | 0.45 | 0.40 | 0.46 | 0.49 | 无进展生存 |
6 | 0.53 | 0.64 | 0.68 | 0.77 | 转移复发 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235190.5A CN103966352B (zh) | 2014-05-29 | 2014-05-29 | Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410235190.5A CN103966352B (zh) | 2014-05-29 | 2014-05-29 | Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103966352A CN103966352A (zh) | 2014-08-06 |
CN103966352B true CN103966352B (zh) | 2015-07-29 |
Family
ID=51236353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410235190.5A Active CN103966352B (zh) | 2014-05-29 | 2014-05-29 | Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103966352B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105063230B (zh) * | 2015-09-15 | 2019-04-05 | 贾瑞鹏 | 一种检测人类前列腺癌特异性基因的环介导等温扩增试剂盒及其应用 |
CN109762905A (zh) * | 2019-03-11 | 2019-05-17 | 天津脉络医学检验有限公司 | 一种用于辅助检测前列腺癌的ddPCR引物组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942523A (zh) * | 2010-10-15 | 2011-01-12 | 邵棠 | 一种检测pca3基因、psa基因的液相芯片法及其诊断试剂盒 |
CN102912030A (zh) * | 2012-11-08 | 2013-02-06 | 端鹏 | 用于前列腺癌早期诊断的引物对、探针和试剂盒 |
CN103740854A (zh) * | 2014-01-29 | 2014-04-23 | 中山大学附属第三医院 | 一种肿瘤标记物及其在制备结直肠癌诊断试剂中的应用 |
-
2014
- 2014-05-29 CN CN201410235190.5A patent/CN103966352B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101942523A (zh) * | 2010-10-15 | 2011-01-12 | 邵棠 | 一种检测pca3基因、psa基因的液相芯片法及其诊断试剂盒 |
CN102912030A (zh) * | 2012-11-08 | 2013-02-06 | 端鹏 | 用于前列腺癌早期诊断的引物对、探针和试剂盒 |
CN103740854A (zh) * | 2014-01-29 | 2014-04-23 | 中山大学附属第三医院 | 一种肿瘤标记物及其在制备结直肠癌诊断试剂中的应用 |
Non-Patent Citations (2)
Title |
---|
前列腺癌相关的部分肿瘤标志物研究进展;张永振等;《泌尿外科杂志(电子版)》;20130331;第5卷(第3期);第39-41页 * |
庄建等;前列腺癌基因3的临床研究进展;《中国医药导报》;20130430;第10卷(第10期);第32-34页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103966352A (zh) | 2014-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Smoczynski et al. | Routine brush cytology and fluorescence in situ hybridization for assessment of pancreatobiliary strictures | |
CN108624688B (zh) | hsa_circ_0012755作为前列腺癌分子靶标在制备药物和试剂盒中的应用 | |
CN106701964B (zh) | 血清外泌体miRNA生物标志物及用于胃癌早期诊断的试剂盒 | |
CN107858435A (zh) | 检测环状RNA circRNA_101835的引物、试剂盒和检测方法及应用 | |
CN103966351B (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备肾癌标志物中的应用及其试剂盒 | |
CN104004840A (zh) | 用于早期筛查与诊断前列腺癌的试剂盒 | |
CN104164474A (zh) | 一种检测尿液中pca3基因和psa基因表达量的荧光定量pcr法及其诊断试剂盒 | |
CN105154581A (zh) | 一种非小细胞肺癌的诊断和预示方法和生物检测试剂盒 | |
CN111808963A (zh) | 一种用于早期肺癌无创筛查的组合物、应用与试剂盒及样本处理方法 | |
CN103966352B (zh) | Pca3、cst1和cst4在制备前列腺癌标志物中的应用及其试剂盒 | |
CN103849683B (zh) | 前列腺癌尿液检测试剂盒及其应用 | |
CN104531863A (zh) | 一种人类尿液中pca3基因检测方法和引物 | |
Abou-Zeid et al. | HOXA9 gene promotor methylation and copy number variation of SOX2 and HV2 genes in cell free DNA: A potential diagnostic panel for non-small cell lung cancer | |
CN104611430A (zh) | 一种人类尿液中tmprss2-erg基因检测方法和引物 | |
CN103966350B (zh) | CST1 mRNA和CST4 mRNA或其编码的蛋白质在制备尿道癌标志物中的应用及其试剂盒 | |
CN103966348B (zh) | CST1mRNA和CST4mRNA或其编码的蛋白质在制备膀胱癌标志物中的应用及其试剂盒 | |
Shan et al. | The influence of prostate volume on clinical parameters in prostate cancer screening | |
CN109554475A (zh) | 用于肺结节良恶性鉴别的基因突变/融合组合及试剂盒 | |
CN105349640A (zh) | 一种用于诊断和预示乳腺癌的生物标志物和检测试剂盒 | |
CN106148562A (zh) | 用于检测前列腺癌的标记物 | |
CN106367526A (zh) | 一种诊断前列腺癌的产品及其应用 | |
CN106367509A (zh) | Loc100128675作为检测前列腺癌的分子标记物及其在诊断试剂盒中的应用 | |
CN106148554A (zh) | 一种用于前列腺癌检测的标志物及其在试剂盒中的应用 | |
Shan et al. | Clinical research analysis based on prostate cancer screening diagnosis | |
CN106282366A (zh) | 一种与前列腺癌相关的分子标记物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: SUZHOU MICRO DIAG BIOMEDICINE CO., LTD. Free format text: FORMER OWNER: SHANGHAI DUWEI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20141103 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201507 JINSHAN, SHANGHAI TO: 215123 SUZHOU, JIANGSU PROVINCE |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20141103 Address after: Suzhou City, Jiangsu Province, Suzhou Industrial Park, 215123 Street No. 218 Nano Technology Park building C4 Room 301 Applicant after: Suzhou Micro Diag Biomedicine Co., Ltd. Address before: 201507 Shanghai city Jinshan District Caojing town industry Road No. 80 Applicant before: SHANGHAI DUWEI MEDICAL TECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151120 Address after: 215000, 99 Industrial Park, Jinji Lake Road, Jiangsu, Suzhou, 16 west of Suzhou Patentee after: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY CO., LTD. Address before: Suzhou City, Jiangsu Province, Suzhou Industrial Park, 215123 Street No. 218 Nano Technology Park building C4 Room 301 Patentee before: Suzhou Micro Diag Biomedicine Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211209 Address after: 200120 all parts of floor 4, building 1, No. 271, Hong Kong Macao Road, pilot Free Trade Zone, Pudong New Area, Shanghai Patentee after: SHANGHAI LIANGRUN BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 215000 building 16, Northwest District, Suzhou nano City, 99 Jinjihu Avenue, Suzhou Industrial Park, Jiangsu Province Patentee before: PUSHI HUAKANG JIANGSU MEDICAL TECHNOLOGY Co.,Ltd. |